SAN
DIEGO, June 5, 2023 /PRNewswire/ -- Cardiff
Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology
company leveraging PLK1 inhibition, a well-validated oncology drug
target, to develop novel therapies across a range of cancers, today
announced that company management will participate in
a company presentation and 1x1 investor meetings at the
Jefferies Healthcare Conference, which is taking place at the
Marriott Marquis in New York from
June 7-9, 2023.
Details of the company presentation can be found below.
Presenters: Mark Erlander,
CEO
Date: 06/08/2023
Time: 10:30 – 10:55 AM ET in Track
2
A replay of the presentation will be available by visiting the
"Events" section of the Cardiff Oncology website following the
completion of the presentation.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company
leveraging PLK1 inhibition, a well-validated oncology drug target,
to develop novel therapies across a range of cancers. The Company's
lead asset is onvansertib, a PLK1 inhibitor being evaluated in
combination with standard-of-care (SoC) therapeutics in clinical
programs targeting indications such as KRAS/NRAS-mutated metastatic
colorectal cancer (mCRC) and metastatic pancreatic ductal
adenocarcinoma (mPDAC), as well as in investigator-initiated trials
in triple negative breast cancer (TNBC) and small cell lung cancer
(SCLC). These programs and the Company's broader development
strategy are designed to target tumor vulnerabilities in order to
overcome treatment resistance and deliver superior clinical benefit
compared to the SoC alone. For more information, please visit
https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com
Investor Contact:
Kiki
Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com
Media Contact:
Richa
Kumari
Taft Communications
551 344-5592
richa@taftcommunications.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-present-at-the-jefferies-healthcare-conference-301838475.html
SOURCE Cardiff Oncology, Inc.